Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.

Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016

Amit Agarwal, MD PhD

The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

Connect® MM- The Multiple Myeloma Disease Registry

Describe practice patterns of common first-line treatment regimens and subsequent therapeutic strategies in patients newly diagnosed with symptomatic MM in the community and academic setting

Provide insight into treatment regimens and therapy sequence in clinical practice as they relate to clinical outcomes (response, overall survival, progression-free survival) in patients newly diagnosed with symptomatic MM

Describe any differences in effectiveness associated with different treatment regimens, including common first-line regimens, subsequent therapeutic strategies and regional effects (such as proximity of academic centers) in patients newly diagnosed with symptomatic MM

Describe the health-related quality of life (HRQoL) of patients newly diagnosed with symptomatic MM, and to explore the association with HRQoL of treatment regimens/sequence and clinical outcomes

Celgene

Lymphoma, Large B-Cell, Diffuse

Lymphoma

Lymphoma, Non-Hodgkin

Lymphoma, Follicular

Lymphoma, B-Cell

Lymphatic Diseases

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Lymphosarcoma

Follicular Lymphoma

First relapsed/refractory diffuse large B-cell lymphoma (DLBCL) participants must have been diagnosed with relapsed/refractory (R/R) disease within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment

First relapsed/refractory (R/R) follicular lymphoma (FL) participants must have been diagnosed with R/R disease (grade 1 to 3B or transformed) within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment

BMS Study Connect Contact Center www.BMSStudyConnect.com

First line of the email MUST contain NCT # and Site #.

David Andorsky, Site 160

Walter Quan, Site 145

Rami Owera, Site 158

Dilawar Khan, Site 104

Daulath Singh, Site 133

Nakhle Saba, Site 152

Tycel Phillips, Site 147

Suzanne Patton, Site 144

Orsini James, Site 163

Bruno Fang, Site 159

Site 140

Kenneth Nahum, Site 141

Ian Horkheimer, Site 138

Darla Liles, Site 151

Site 156

David Aboulafia, Site 150

Francis Senecal, Site 167

Bristol-Myers Squibb

The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).

This Disease Registry is designed to capture the patient characteristics, practice patterns, and therapeutic strategies evaluated in community and academic centers when treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), and R/R follicular lymphoma (FL). The data collected in this Registry will facilitate the evaluation of the current treatment landscape for non-Hodgkin lymphoma (NHL), including the clinical effectiveness, safety. No investigational product or drug will be administered as part of this study. Enrolled patients will receive treatment and evaluations for their disease according to the standard of care and routine clinical practice at each study site. All treatments that patients receive for their disease will be recorded, including any previous lymphoma treatments. Clinical outcomes will be documented as part of an objective clinical assessment. In addition, patient-reported health-related quality of life (HRQoL) outcomes data will be collected from patients using various validated instruments. Social support data will also be collected.

Collect, store, and test tumor biopsies, blood, plasma, DNA and RNA samples

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Information relating to our policy on data sharing and the process for requesting data can be found at the following link:

https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Describe patient characteristics in community and academic settings

Evaluate the effectiveness of various treatments on progression-free survival (PFS)

Evaluate the effectiveness of various treatments on event free survival (EFS)

Evaluate the effectiveness of various treatments on the overall response rate (ORR)

Evaluate the effectiveness of various treatments on time to next treatment (TTNT)

Evaluate the effectiveness of various treatments on Overall Survival (OS)

Describe practice patterns in community and academic settings

Describe therapeutic strategies in community and academic settings

Describes changing treatment landscape over time

Describes factors associated with treatment choice, including CAR T-cell and non-CAR T-cell therapies

Describe safety outcomes associated with treatment regimens (adverse events of interest \[AEIs\]and SAEs)

Describe patient-reported HRQoL outcomes among the overall cohort population and among patient subgroups of interest (e.g.,age, risk, treatment regimen, disease subtype)

Describe patient-reported health-related quality of life (HRQoL) outcomes among the overall cohort population and among patient subgroups of interest (e.g. age, risk, treatment regimen, disease subtype)

Study title	NCT ID	Conditions	Eligibility	Organization
Connect® MM- The Multiple Myeloma Disease Registry	NCT01081028	Multiple Myelom...	18 Years -	Celgene
Connect® MM- The Multiple Myeloma Disease Registry	NCT01081028	Multiple Myelom...	18 Years -	Celgene
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study	NCT04982471	Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Folli...	18 Years -	Celgene

Spots Global Cancer Trial Database for connect®

Every month we try and update this database with for connect® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for connect®

Every month we try and update this database with for connect® cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for connect® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.